Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000659047 | SCV000780851 | likely benign | not provided | 2024-07-01 | criteria provided, single submitter | clinical testing | TNXB: BP4, BS2 |
Gene |
RCV000659047 | SCV001861935 | benign | not provided | 2020-11-24 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV002279476 | SCV002566263 | benign | Ehlers-Danlos syndrome | 2022-07-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002334223 | SCV002636124 | likely benign | Cardiovascular phenotype | 2021-06-15 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Genome Diagnostics Laboratory, |
RCV000659047 | SCV001809682 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000659047 | SCV001930183 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000659047 | SCV002038041 | likely benign | not provided | no assertion criteria provided | clinical testing |